[
    [
        {
            "time": "2021-03-15",
            "original_text": "Top Stock Reports for Oracle, Eli Lilly & BP",
            "features": {
                "keywords": [
                    "Oracle",
                    "Eli Lilly",
                    "BP"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology",
                    "pharmaceuticals",
                    "energy"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Top Stock Reports for Oracle, Eli Lilly & BP",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-04-20",
            "original_text": "Lilly's (LLY) JAK Inhibitor Olumiant Fails COVID-19 Study",
            "features": {
                "keywords": [
                    "Lilly",
                    "JAK",
                    "Inhibitor",
                    "Olumiant",
                    "COVID-19",
                    "Study"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Lilly's (LLY) JAK Inhibitor Olumiant Fails COVID-19 Study",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-05-10",
            "original_text": "Pharma Stock Roundup: FDA Decision Delays for PFE, LLY, ABBV, AZN Vaccine Woes",
            "features": {
                "keywords": [
                    "FDA",
                    "Decision",
                    "Delays",
                    "PFE",
                    "LLY",
                    "ABBV",
                    "AZN",
                    "Vaccine"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: FDA Decision Delays for PFE, LLY, ABBV, AZN Vaccine Woes",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-06-05",
            "original_text": "NIH recommends Lilly and Regeneron's combination antibody treatments to people with mild and moderate COVID-19",
            "features": {
                "keywords": [
                    "NIH",
                    "Lilly",
                    "Regeneron",
                    "antibody",
                    "treatments",
                    "COVID-19"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "NIH recommends Lilly and Regeneron's combination antibody treatments to people with mild and moderate COVID-19",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-07-12",
            "original_text": "Provention Bio Shares Crash 40% Due To Regulatory Setback For Diabetes Drug",
            "features": {
                "keywords": [
                    "Provention Bio",
                    "Shares",
                    "Crash",
                    "Regulatory",
                    "Setback",
                    "Diabetes",
                    "Drug"
                ],
                "sentiment_score": -0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Provention Bio Shares Crash 40% Due To Regulatory Setback For Diabetes Drug",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-18",
            "original_text": "Provention Bio Stock Craters After FDA Flags Deficiencies In PK Profiles From Teplizumab Trials For Diabetes",
            "features": {
                "keywords": [
                    "Provention Bio",
                    "Stock",
                    "Craters",
                    "FDA",
                    "Deficiencies",
                    "PK Profiles",
                    "Teplizumab",
                    "Trials",
                    "Diabetes"
                ],
                "sentiment_score": -0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Provention Bio Stock Craters After FDA Flags Deficiencies In PK Profiles From Teplizumab Trials For Diabetes",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]